WHO Sounds Alert Over Severe Scarcity of Weight-Loss Jabs

Under one in 10 people eligible to benefit from weight-loss injections like Wegovy have access to them, states the global health agency as it issues its inaugural guidance on the medications.

Given in excess of 1,000,000,000 people worldwide currently obese, it is calling for increased and just access to this class of drugs.

Based on projections, in excess of 2,000,000,000 will be living with obesity by 2030 without intervention.

"Our latest guidelines affirms that obesity is a lifelong illness that can be treated with comprehensive and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.

High costs, insufficient output, and supply-chain constraints are significant hurdles to broad access to the jabs that can aid individuals in losing significant body mass, explains the agency.

Skinny Jab Supply Crisis

Even under the present best projected scenario, the supply of these medications might only reach around 100 million people – under 10% of the global need, per the health organization.

The recommendation urges nations and manufacturers to increase access, via approaches including voluntary licensing.

The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is due to expire in a number of countries in 2026.

How Obesity Jabs Operate

These medications replicate a natural hormone to delay gastric emptying, reduce hunger and boost satiety so users consume fewer calories.

Individuals usually see weight reduction after several weeks of starting on the once-weekly jabs.

Studies indicates patients may regain a significant portion after a year of discontinuing the medication, as their usual hunger return.

Being carrying excess weight elevates your likelihood for experiencing medical conditions, like diabetes, cardiovascular issues, stroke, and specific malignancies.

Excess weight impacts people in every country and was linked to 3.7 million deaths worldwide in 2024, according to the WHO.